# The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

> **NCT04630964** · PHASE2 · COMPLETED · sponsor: **Section for Affective Disorders; Northern Stockholm Psychiatry** · enrollment: 35 (actual)

## Conditions studied

- Major Depressive Disorder
- Depression

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Niacin

## Key facts

- **NCT ID:** NCT04630964
- **Lead sponsor:** Section for Affective Disorders; Northern Stockholm Psychiatry
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2023-04-19
- **Final completion:** 2024-04-18
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630964, "The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04630964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*